ConductScience.org, home

Paper26475367

Hypereosinophilic Syndrome.

Curtis C and 1 other. Clin Rev Allergy Immunol, 2016. Cited by 138 papers, by iCite.

Cite this record

ConductScience Library. Hypereosinophilic Syndrome. Papers, record 26475367. Release papers-2026-11-12-0.1.0, 12 Nov 2026. https://conductscience.org/library/papers/26475367

Download JSON
Sources
11 sources
Release
papers-2026-11-12-0.1.0

Paper

PubMed's record of the paper, with iCite's citation figures. No abstract is shown.

Title
Hypereosinophilic Syndrome.
PubMed
Journal
Clin Rev Allergy Immunol
PubMed
Year
2016
PubMed
Publication types
Journal Article, Review
PubMed
Citations, by iCite
138
iCite
Relative citation ratio, by iCite
5.99
iCite
Revised in PubMed
2022-08-01
PubMed

Authors2

The authors in the order PubMed's record lists them, with the ORCID iDs it states.

OrderAuthorForenameKindORCID iD
1Curtis CCaseyhttps://orcid.org/0000-0003-3169-0705
2Ogbogu PPrincess

Source PubMed

Download CSV of authors

Topics6

NLM's MeSH indexing of the paper, its major topics first.

MeSH termMajor
Hypereosinophilic SyndromeMajor topic
Combined Modality Therapy
Diagnosis, Differential
Disease Management
Humans
Treatment Outcome

References47

The papers the reference list in PubMed's record names, those in our copy of PubMed, in the list's order.

OrderPMIDTitleJournalYearIn PapersSource
112660384A tyrosine kinase created by fusion of the PDGFRA and FIP1L1 genes as a therapeutic target of imatinib in idiopathic hypereosinophilic syndrome.N Engl J Med2003https://conductscience.org/library/papers/12660384PubMed
218344568Treatment of patients with the hypereosinophilic syndrome with mepolizumab.N Engl J Med2008https://conductscience.org/library/papers/18344568PubMed
324407160Identification of Ponatinib as a potent inhibitor of growth, migration, and activation of neoplastic eosinophils carrying FIP1L1-PDGFRA.Exp Hematol2014https://conductscience.org/library/papers/24407160PubMed
420639008Refining the definition of hypereosinophilic syndrome.J Allergy Clin Immunol2010https://conductscience.org/library/papers/20639008PubMed
521761433World Health Organization-defined eosinophilic disorders: 2011 update on diagnosis, risk stratification, and management.Am J Hematol2011https://conductscience.org/library/papers/21761433PubMed
617868859Cardiovascular manifestations of hypereosinophilic syndromes.Immunol Allergy Clin North Am2007https://conductscience.org/library/papers/17868859PubMed
72088325Interferon-alpha for the hypereosinophilic syndrome.Ann Intern Med1990https://conductscience.org/library/papers/2088325PubMed
816406016FIP1L1-PDGFRA in eosinophilic disorders: prevalence in routine clinical practice, long-term experience with imatinib therapy, and a critical review of the literature.Leuk Res2006https://conductscience.org/library/papers/16406016PubMed
919630574Hypereosinophilic syndrome: current approach to diagnosis and treatment.Annu Rev Med2009https://conductscience.org/library/papers/19630574PubMed
1017868858Gastrointestinal eosinophilia.Immunol Allergy Clin North Am2007https://conductscience.org/library/papers/17868858PubMed
1117868860Pulmonary eosinophilic syndromes.Immunol Allergy Clin North Am2007https://conductscience.org/library/papers/17868860PubMed
1218004179Management of hypereosinophilic syndrome: a prospective study in the era of molecular genetics.Medicine (Baltimore)2007https://conductscience.org/library/papers/18004179PubMed
13497706Strongyloides stercoralis infection in former Far East prisoners of war.Br Med J1979https://conductscience.org/library/papers/497706PubMed
1417868857Dermatologic manifestations of the hypereosinophilic syndromes.Immunol Allergy Clin North Am2007https://conductscience.org/library/papers/17868857PubMed
159758611Familial eosinophilia maps to the cytokine gene cluster on human chromosomal region 5q31-q33.Am J Hum Genet1998https://conductscience.org/library/papers/9758611PubMed
1623040887Long-term safety of mepolizumab for the treatment of hypereosinophilic syndromes.J Allergy Clin Immunol2013https://conductscience.org/library/papers/23040887PubMed
1722935585Novel targeted therapies for eosinophilic disorders.J Allergy Clin Immunol2012https://conductscience.org/library/papers/22935585PubMed
1817868856Lymphocytic variant hypereosinophilic syndromes.Immunol Allergy Clin North Am2007https://conductscience.org/library/papers/17868856PubMed
1918664881Eosinophilic gastrointestinal diseases (EGIDs).J Pediatr Gastroenterol Nutr2008https://conductscience.org/library/papers/18664881PubMed
2014726461Strongyloides stercoralis in the Immunocompromised Population.Clin Microbiol Rev2004https://conductscience.org/library/papers/14726461PubMed

See all 47 referencesDownload CSV of references

Cited by102

The papers in our copy of PubMed whose reference list names this one, newest first. iCite, which reads more sources, counts 138 citations.

PMIDTitleJournalYearIn PapersSource
42927137A Case of Idiopathic Hypereosinophilic Syndrome With High WT1 (Wilms' Tumor Gene) mRNA.Cureus2026https://conductscience.org/library/papers/42927137PubMed
42824263A Retrospective Review of 1821 Cases of Eosinophilia in a Single-Center Study in Eastern China.EJHaem2026https://conductscience.org/library/papers/42824263PubMed
42688267Hypereosinophilic syndrome with Löffler endocarditis and multiple cerebral infarctions in a patient with a CLL-phenotype clonal B-cell population: a case report.Front Cardiovasc Med2026https://conductscience.org/library/papers/42688267PubMed
42657158
Mepolizumab reduces systemic corticosteroid-related toxicities and healthcare burden in patients with eosinophilic granulomatosis with polyangiitis and hypereosinophilic syndrome: a retrospective database study.
Front Allergy2026https://conductscience.org/library/papers/42657158PubMed
42513483Organ Involvement and Constitutional Symptoms in Idiopathic Hypereosinophilic Syndrome: A 72-Patient Single-Centre Cohort.J Clin Med2026https://conductscience.org/library/papers/42513483PubMed
42014519Al18F-FAPI PET/CT in hypereosinophilic syndrome with cardiac involvement and its potential association with eosinophil extracellular traps.Eur J Nucl Med Mol Imaging2026https://conductscience.org/library/papers/42014519PubMed
41833286Redefining Hematology Referral Thresholds for Eosinophilia.Eur J Haematol2026https://conductscience.org/library/papers/41833286PubMed
41567200From hypereosinophilia to hypereosinophilic syndrome: real-world application of a two-tailed approach for HES diagnosis.Front Immunol2025https://conductscience.org/library/papers/41567200PubMed
41415327Refractory erythroderma in idiopathic hypereosinophilic syndrome: A case treated with mepolizumab and abrocitinib.SAGE Open Med Case Rep2025https://conductscience.org/library/papers/41415327PubMed
41322417Mepolizumab for hypereosinophilic syndrome: effectiveness and safety from real-world evidence.Front Immunol2025https://conductscience.org/library/papers/41322417PubMed
41209273
Idiopathic hypereosinophilic syndrome complicated by computed tomography-negative cerebral infarction, strangulated intestinal obstruction, and hepatic portal venous gas: a case report of multi-system involvement.
Quant Imaging Med Surg2025https://conductscience.org/library/papers/41209273PubMed
40943043Paradoxical Use of Benralizumab in Reactive Hypereosinophilia from Toxocariasis and Tuberculosis Co-Infection-Case Report and Literature Review.Int J Mol Sci2025https://conductscience.org/library/papers/40943043PubMed
40656763Burden of hypereosinophilic syndromes in the United States: Patients' perspective.J Allergy Clin Immunol Glob2025https://conductscience.org/library/papers/40656763PubMed
40630493Primary care physicians play a crucial role in diagnosing and managing rare eosinophilic diseases: HES and EGPA.Front Med (Lausanne)2025https://conductscience.org/library/papers/40630493PubMed
40486501Steroid-sparing benefits of biologic use in hypereosinophilic syndrome and substantial disease burden across subtypes.Front Allergy2025https://conductscience.org/library/papers/40486501PubMed
40418815Tracking Public Interest in Rare Diseases and Eosinophilic Disorders in Germany: Web Search Analysis.JMIR Infodemiology2025https://conductscience.org/library/papers/40418815PubMed
40396537Hypereosinophilia: clinical and therapeutic approach in 2025.Curr Opin Allergy Clin Immunol2025https://conductscience.org/library/papers/40396537PubMed
40382631Benralizumab for acute thromboembolism in hypereosinophilic syndrome: a case report.Allergy Asthma Clin Immunol2025https://conductscience.org/library/papers/40382631PubMed
40297299Eosinophilic Granulomatous Polyangiitis with Autoimmune Hemolytic Anemia: A Case Report and Review of the Literature.J Asthma Allergy2025https://conductscience.org/library/papers/40297299PubMed
40283978Biologic Agents in Idiopathic Hypereosinophilic Syndrome.Pharmaceuticals (Basel)2025https://conductscience.org/library/papers/40283978PubMed

See all 102 cited byDownload CSV of cited by

Data dates

The date of each source this release read.

PubMed
2026-11-06
PubMed
iCite
2026-11-05
iCite
PMC's ID file
2026-11-05
PMC's ID file
NIH RePORTER's grant and paper links
2026-11-01
NIH RePORTER's grant and paper links
Trials
2026-11-12
Gene search
2026-11-11
Pipelines
2026-09-18

None in this release

  • Grants
  • Trials
  • Comments and corrections
  • Genes
  • Drugs
  • Data

Sources 11

  • ChEMBL, through Open TargetsCC BY-SA 3.0
  • ClinicalTrials.govNo license stated
  • HGNCCC0
  • iCiteCC BY 4.0
  • NCBI GenePublic domain (US government)
  • NIH RePORTER's grant and paper linksPublic domain
  • Open TargetsCC0 1.0
  • PMC's ID filePublic domain (US government)
  • PubMedNLM's terms
  • PubTator 3Public domain
  • UniProtCC BY 4.0
Each source's terms
  • ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
  • ClinicalTrials.govnone stated
  • HGNCCC0: https://www.genenames.org/about/license/
  • iCiteCC BY 4.0
  • NCBI GeneNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
  • NIH RePORTER's grant and paper linksPublic domain (NIH RePORTER)
  • Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
  • PMC's ID fileNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
  • PubMedNLM's terms
  • PubTator 3Public domain
  • UniProtCC BY 4.0. UniProt's licence file: "All databases and documents in the UniProt FTP directory may be copied and redistributed freely, without advance permission, provided that this copyright statement is reproduced with each copy." UniProt asks that users cite its latest paper: The UniProt Consortium, UniProt: the Universal Protein Knowledgebase in 2025, Nucleic Acids Research 53:D609-D617, https://doi.org/10.1093/nar/gkae1010. Read on 9 Nov 2026 at https://www.uniprot.org/help/license

ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.

For software

Read this paper from software.

The record and each of its lists are JSON, twenty rows a page. No key.

GET https://conductscience.org/api/papers/v1/26475367

GET https://conductscience.org/api/papers/v1/26475367/references?page=2